Article

Patients with History of Breast Cancer Face Increased Risk of Heart Disease

Study finds elevated risk factors for cardiovascular disease in postmenopausal women with a history of breast cancer.

A new study published in Menopause, a journal through the North American Menopause Society (NAMS), has found that postmenopausal women with breast cancer are at greater risk for developing heart disease.

The study included 96 postmenopausal patients with a history of breast cancer and compared them with 192 postmenopausal women. Groups were matched by age, time since menopause, and body mass index. The purpose of the study was to compare and evaluate risk factors for cardiovascular disease in postmenopausal women with a history of breast cancer to women without a history of breast cancer.

The investigators found that postmenopausal women with a history of breast cancer showed a stronger association with metabolic syndrome, diabetes, atherosclerosis, hypertriglyceridemia, and abdominal obesity, which are major risk factors for cardiovascular disease. They also found that the risk of cardiovascular mortality increased to match mortality rates from cancer.

Cardiovascular disease is the main cause of death in postmenopausal women, and women treated for breast cancer are at a greater risk of developing heart disease than those who do not have a history of the disease. According to the press release, cardiovascular events may occur more than 5 years after radiation exposure, which may persist for up to 30 years.

"Heart disease appears more commonly in women treated for breast cancer because of the toxicities of chemotherapy, radiation therapy, and use of aromatase inhibitors, which lower estrogen. Heart-healthy lifestyle modifications will decrease both the risk of recurrent breast cancer and the risk of developing heart disease," said JoAnn Pinkerton, MD, executive director of NAMS. "Women should schedule a cardiology consultation when breast cancer is diagnosed and continue with ongoing follow-up after cancer treatments are completed."

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards